United Therapeutics CFO sells 10K shares in plan
United Therapeutics CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share, then sold 10,000 shares in open-market trades on April 22–23, 2026 under a Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
United Therapeutics CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share, then sold 10,000 shares in open-market trades on April 22–23, 2026 under a Rule 10b5-1 trading plan.
Sale prices for the common stock ranged around the mid-$570s per share across multiple trades. Following these transactions, he directly holds 18,876 shares of United Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.72M)
Approx. gross sale proceeds
$5.72M
Approx. exercise cost
$1.35M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 280 | $569.6254 | $159K |
| Sale | Common Stock | 1,079 | $570.8161 | $616K |
| Sale | Common Stock | 3,325 | $571.6436 | $1.90M |
| Sale | Common Stock | 3,976 | $572.6619 | $2.28M |
| Sale | Common Stock | 321 | $573.5119 | $184K |
| Sale | Common Stock | 535 | $574.7937 | $308K |
| Sale | Common Stock | 120 | $576.6167 | $69K |
| Sale | Common Stock | 364 | $575.8451 | $210K |
Holdings After Transaction:
Stock Option — 62,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (9)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $569.19 to $570.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $570.19 to $571.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $571.19 to $572.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $572.19 to $573.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $573.22 to $574.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $574.28 to $575.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $575.30 to $576.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $576.45 to $576.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Shares sold: 10,000 shares
Option exercise shares: 10,000 shares
Option strike price: $135.42 per share
+3 more
6 metrics
Shares sold
10,000 shares
Open-market sales of common stock on April 22–23, 2026
Option exercise shares
10,000 shares
Stock options exercised into common stock
Option strike price
$135.42 per share
Exercise price for stock options converted on April 23, 2026
Post-transaction holdings
18,876 shares
Directly owned United Therapeutics common stock after all trades
Sale price range examples
$569.19–$576.93 per share
Price ranges for multiple trades noted in footnotes
Rule 10b5-1 plan date
October 31, 2025
Date CFO entered into pre-arranged trading plan
Key Terms
Rule 10b5-1 trading plan, stock options, open-market sale, weighted average price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond report in this Form 4?
CFO James Edgemond reported exercising options for 10,000 United Therapeutics shares, then selling 10,000 common shares in open-market trades around the mid-$570s per share. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan on April 22–23, 2026.
What stock options did the United Therapeutics (UTHR) CFO exercise?
He exercised stock options covering 10,000 shares of United Therapeutics common stock at a strike price of $135.42 per share. These options were reflected as a derivative transaction, converting the option position into common shares that were then sold in the open market.
Were the United Therapeutics (UTHR) CFO’s trades made under a Rule 10b5-1 plan?
Yes. The filing states the option exercise and subsequent share sales were executed pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025. Such plans pre-schedule trades, indicating the timing was determined in advance rather than by day-to-day market decisions.
Does this United Therapeutics (UTHR) Form 4 show any remaining options for the CFO?
The filing shows an exercise of stock options for 10,000 shares, reducing that specific derivative position. The derivative summary in the provided data is empty, indicating no remaining derivative positions from this particular option grant are reported in this Form 4 excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.
